BeiGene
BGNE
#878
Rank
โ‚น1.918 T
Marketcap
โ‚น16,332
Share price
-5.56%
Change (1 day)
-1.40%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Earnings for BeiGene (BGNE)

Earnings in 2024 (TTM): -โ‚น73.82 Billion

According to BeiGene 's latest financial reports the company's current earnings are โ‚น3.09 Billion. In 2023 the company made an earning of -โ‚น101.87 Billion, an increase over its 2022 earnings that were of -โ‚น150.95 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for BeiGene from 2015 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -โ‚น73.82 Billion-27.53%
2023 -โ‚น101.87 Billion-32.52%
2022 -โ‚น150.95 Billion24.39%
2021 -โ‚น121.35 Billion-13.21%
2020 -โ‚น139.82 Billion72.69%
2019 -โ‚น80.97 Billion36.01%
2018 -โ‚น59.53 Billion616.83%
2017 -โ‚น8.31 Billion-15.24%
2016 -โ‚น9.8 Billion107.91%
2015 -โ‚น4.72 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-โ‚น1.54 Billion-97.95%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น20.64 Billion-72.40%๐Ÿ‡บ๐Ÿ‡ธ USA